Showing 4261-4270 of 8827 results for "".
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the
- New Microneedle Patch May Treat Acne Without Antibioticshttps://practicaldermatology.com/news/new-microneedle-patch-may-treat-infected-acne-without-antibiotics/2461826/Researchers out of the University of Hong Kong (HKUMed) have designed a new microneedle patch that offers a non-antibiotic approach for the treatment of infected acne. The design is engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) antibacterial nanoparticle
- Fifth Piece of Art Added to Boehringer Ingelheim, FIT's DTech Unwearable Collectionhttps://practicaldermatology.com/news/fifth-piece-of-art-added-to-boehringer-ingelheim-fits-dtech-unwearable-collection/2461825/In partnership with the Fashion Institute of Technology's (FIT) DTech Lab and world-renowned designer, Bart Hess, Boehringer Ingelheim is introducing a fifth piece to The Unwearable Collection, an art collection that uses raw materials like paper and glass to uniquely illustrat
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- Scleroderma Research Update from Cedars-Sinai’s Kao Autoimmunity Institutehttps://practicaldermatology.com/news/scleroderma-research-update-from-cedars-sinais-kao-autoimmunity-institute/2461818/An estimated 100,000 people in the U.S. are living with scleroderma, an autoimmune disease characterized by thickening and scarring of the skin and vital organs, and the narrowing of the blood vessels which lead to poor circulation. Tthere are about 7,000 to 8,000 new cases every year.
- A Sneak Peek in the AD Pike: Aslan’s Eblasakimab Blocks IL-13Rα1, Inhibits Activation of STAT6https://practicaldermatology.com/news/a-sneak-peek-in-the-ad-pike-aslans-eblasakimab-blocks-il-13ra1-inhibits-activation-of-stat6/2461821/Aslan's eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, is showing promise in atopic dermatitis (AD), according to part of a phase 1a, open-label, single ascending dose
- Topline Phase 2b Data: Amlitelimab Performs Well in ADhttps://practicaldermatology.com/news/topline-phase-2b-data-amlitelimab-performs-well-in-ad/2461820/Sanofi’s amlitelimab showed statistically significant improvements in signs and symptoms of moderate-to-severe atopic dermatitis in adults, according to topline Phase 2b data. Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune re
- News Your Patients Can Use: AAD Offers Sun Protection Counsel in Advance of Independence Day Holiday Weekendhttps://practicaldermatology.com/news/news-your-patients-can-use-aad-offers-sun-protection-counsel-in-advance-of-independence-day-holiday-weekend/2461819/Remind your patients to use sunscreen on the July 4th weekend and on the days, weeks, and months that follow. A recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults revealed that one-third of American parents reported having a child who
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) f
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe